<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK304122" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK304122/" /><meta name="ncbi_pagename" content="Sepiapterin Reductase Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Sepiapterin Reductase Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Sepiapterin Reductase Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/07/01" /><meta name="citation_author" content="Jennifer Friedman" /><meta name="citation_pmid" content="26131547" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK304122/" /><meta name="citation_keywords" content="Dopa-Responsive Hypersomnia" /><meta name="citation_keywords" content="DYT-SPR" /><meta name="citation_keywords" content="SPR Deficiency" /><meta name="citation_keywords" content="SPR Deficiency" /><meta name="citation_keywords" content="Dopa-Responsive Hypersomnia" /><meta name="citation_keywords" content="DYT-SPR" /><meta name="citation_keywords" content="Sepiapterin reductase" /><meta name="citation_keywords" content="SPR" /><meta name="citation_keywords" content="Sepiapterin Reductase Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Sepiapterin Reductase Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Jennifer Friedman" /><meta name="DC.Date" content="2015/07/01" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK304122/" /><meta name="description" content="The phenotypic spectrum of sepiapterin reductase deficiency (SRD), which ranges from significant motor and cognitive deficits to only minimal findings, has not been completely elucidated. Clinical features in the majority of affected individuals include motor and speech delay, axial hypotonia, dystonia, weakness, and oculogyric crises; symptoms show diurnal fluctuation and sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, and drowsiness). Most affected individuals have nonspecific features in infancy including developmental delays and axial hypotonia; other features develop over time." /><meta name="og:title" content="Sepiapterin Reductase Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="The phenotypic spectrum of sepiapterin reductase deficiency (SRD), which ranges from significant motor and cognitive deficits to only minimal findings, has not been completely elucidated. Clinical features in the majority of affected individuals include motor and speech delay, axial hypotonia, dystonia, weakness, and oculogyric crises; symptoms show diurnal fluctuation and sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, and drowsiness). Most affected individuals have nonspecific features in infancy including developmental delays and axial hypotonia; other features develop over time." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK304122/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/spr-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK304122/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B7252E03FE831000000000A29039C.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK304122_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK304122_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/schwann/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/scad/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK304122_"><span class="title" itemprop="name">Sepiapterin Reductase Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Dopa-Responsive Hypersomnia, DYT-SPR, SPR Deficiency</div><p class="contrib-group"><span itemprop="author">Jennifer Friedman</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK304122_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK304122_ai__"><div class="contrib half_rhythm"><span itemprop="author">Jennifer Friedman</span>, MD<div class="affiliation small">Clinical Professor, Neurosciences and Pediatrics<br />University of California San Diego/Rady Children&#x02019;s Hospital San Diego<br />San Diego, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.dshcr@namdeirfrj" class="oemail">gro.dshcr@namdeirfrj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 1, 2015</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="spr-def.Summary" itemprop="description"><h2 id="_spr-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The phenotypic spectrum of sepiapterin reductase deficiency (SRD), which ranges from significant motor and cognitive deficits to only minimal findings, has not been completely elucidated. Clinical features in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals include motor and speech delay, axial hypotonia, dystonia, weakness, and oculogyric crises; symptoms show diurnal fluctuation and sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, and drowsiness). Most affected individuals have nonspecific features in infancy including developmental delays and axial hypotonia; other features develop over time.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of sepiapterin reductase deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SPR</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> or characteristic abnormalities of CSF neurotransmitters and pterins.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> L-dopa in combination with carbidopa (or another peripheral decarboxylase inhibitor) is the main therapy used to correct CNS dopamine deficiency; 5-hydroxytryptophan (5-HTP), also in combination with carbidopa, has shown additional clinical benefit in some. When L-dopa/5HTP/carbidopa are not tolerated or sufficiently effective some individuals may benefit from use of other agents such as monoamine oxidase inhibitors, serotonin reuptake inhibitors, melatonin, dopamine agonists, anticholinergics, and methylphenidate. These medications most consistently correct motor abnormalities; however, in some individuals cognitive manifestations remain more refractory.</p><p><i>Prevention of secondary complications:</i> Physical, occupational, and speech therapy may improve or maintain motor function.</p><p><i>Surveillance:</i> Data are insufficient to determine how frequently CSF levels of dopamine and serotonin metabolites should be evaluated and whether these levels should be used to adjust medication doses.</p><p><i>Agents/circumstances to avoid:</i> Although adverse events with specific agents have not been reported in persons with SRD, the following should be avoided on a theoretic basis: sulfa drugs, methotrexate, nitrous oxide, neuroleptics, and other dopamine antagonists (e.g., metoclopramide).</p><p><i>Evaluation of relatives at risk:</i> Although no data on outcomes are available, it is appropriate to use <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>SPR</i> pathogenic variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and/or analysis of CSF neurotransmitter metabolites and pterins to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as soon as possible those who would benefit from early initiation of treatment to correct CNS dopamine and serotonin deficiency.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>SRD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <i>SPR</i> pathogenic variants in the family are known.</p></div></div><div id="spr-def.Diagnosis"><h2 id="_spr-def_Diagnosis_">Diagnosis</h2><p>No formal diagnostic criteria for sepiapterin reductase deficiency (SRD) have been published. A diagnostic algorithm is presented in a recent review [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>].</p><div id="spr-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Sepiapterin reductase deficiency (SRD) should be suspected in individuals with characteristic clinical findings. The phenotypic spectrum is broad and suggestive signs are often nonspecific.</p><p>Core clinical features present in more than 65% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals:</p><ul><li class="half_rhythm"><div>Motor and speech delay</div></li><li class="half_rhythm"><div>Axial hypotonia</div></li><li class="half_rhythm"><div>Dystonia</div></li><li class="half_rhythm"><div>Weakness</div></li><li class="half_rhythm"><div>Oculogyric crises</div></li><li class="half_rhythm"><div>Diurnal fluctuation and symptom improvement with sleep</div></li></ul><p>Other common features:</p><ul><li class="half_rhythm"><div>Intellectual disability</div></li><li class="half_rhythm"><div>Limb hypertonia and hyperreflexia</div></li><li class="half_rhythm"><div>Parkinsonian signs (tremor, bradykinesia, masked facies, rigidity)</div></li><li class="half_rhythm"><div>Psychiatric and/or behavioral abnormalities</div></li><li class="half_rhythm"><div>Sleep disturbances (hypersomnolence, difficulty initiating or maintaining sleep, drowsiness)</div></li><li class="half_rhythm"><div>Autonomic dysfunction (excessive sweating, ptosis, nasal congestion, temperature instability)</div></li></ul><p>Individuals with any of the following three broad sets of findings should be considered to possibly have SRD [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]:</p><ul><li class="half_rhythm"><div>Developmental delays with axial hypotonia</div></li><li class="half_rhythm"><div>Unexplained "cerebral palsy," especially if dystonia is present</div></li><li class="half_rhythm"><div>An L-dopa-responsive motor disorder that may include dystonia. L-dopa responsiveness is evaluated in the following manner: L-dopa (in combination with 10%-25% carbidopa) may be introduced at 1 mg/kg/day and advanced slowly by 1 mg/kg/day over days/weeks monitoring for symptomatic improvement and side effects as the dose is raised. Although data are insufficient to provide precise dosing guidelines, benefit is most often achieved at low dose and is dramatic and rapid (hours to days). Because the response may be delayed or require a high dose (&#x02265;10 mg/kg/d) (as has been observed in <a href="/books/n/gene/drd/">cyclohydrolase 1-deficient dopa-responsive dystonia</a> [DYT-GCH1]), the dose should be increased and maintained for two to four weeks &#x02013; barring side effects &#x02013; to fully assess efficacy of L-dopa [Author, personal observation].</div></li></ul><p>Note: Given the broad range of neurologic manifestations (from asymptomatic to severe global developmental delay) and dramatic response to L-dopa, clinicians should maintain a high index of suspicion for SRD or other monoamine neurotransmitter disorders (see <a href="#spr-def.Differential_Diagnosis">Differential Diagnosis</a>) in individuals with unexplained neurologic dysfunction.</p></div><div id="spr-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of sepiapterin reductase deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by detection of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>SPR</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK304122/table/spr-def.T.molecular_genetic_testing_used/?report=objectonly" target="object" rid-figpopup="figsprdefTmoleculargenetictestingused" rid-ob="figobsprdefTmoleculargenetictestingused">Table 1</a>) or characteristic abnormalities of CSF neurotransmitters and pterins.</p><p>Note: (1) While analysis of either sepiapterin reductase enzyme activity in fibroblasts or pterin levels in cytokine stimulated fibroblasts could be considered [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</a>], neither test is widely available or commonly used. (2) A phenylalanine load test [<a class="bk_pop" href="#spr-def.REF.hyland.1997.1290">Hyland et al 1997</a>], which is not commonly used, could be considered when molecular testing and analysis of CSF neurotransmitters are not available. While an abnormal phenylalanine load is suggestive, it is not diagnostic of SRD, as abnormal results are observed in other BH<sub>4</sub> deficiencies (including <a href="/books/n/gene/drd/">DYT-GCH1</a>).</p><p><b>Molecular genetic testing</b> approaches may include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis is performed first, followed by consideration of gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found in an individual with characteristic clinical findings and/or abnormalities of CSF metabolites. Note: To date no <i>SPR</i> deletions or duplications requiring gene-targeted deletion/duplication analysis have been reported.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SPR</i> and other genes of interest (see <a href="#spr-def.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="spr-def.T.molecular_genetic_testing_used" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Sepiapterin Reductase Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK304122/table/spr-def.T.molecular_genetic_testing_used/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spr-def.T.molecular_genetic_testing_used_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPR</i></td><td headers="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All sequence variants reported to date&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_spr-def.T.molecular_genetic_testing_used_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="spr-def.TF.1.1"><p class="no_margin">See <a href="/books/NBK304122/#spr-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="spr-def.TF.1.2"><p class="no_margin">See <a href="#spr-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="spr-def.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="spr-def.TF.1.4"><p class="no_margin">A total of approximately 50 probands have been reported to date [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>, <a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>, <a class="bk_pop" href="#spr-def.REF.neville.2005.2291">Neville et al 2005</a>, <a class="bk_pop" href="#spr-def.REF.abeling.2006.116">Abeling et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.echenne.2006.308">Echenne et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2006.2032">Friedman et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.verbeek.2008.403">Verbeek et al 2008</a>, <a class="bk_pop" href="#spr-def.REF.clot.2009.1753">Clot et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.kusmierska.2009.s5">Kusmierska et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.leusemenescu.2010.307">Leu-Semenescu et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.mazzuca.2010">Mazzuca et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.wali.2010.954">Wali et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.arrabal.2011.183">Arrabal et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.dill.2012.e29">Dill et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.thibert.2012.79">Thibert et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>, <a class="bk_pop" href="#spr-def.REF.koht.2014.7">Koht et al 2014</a>].</p></div></dd><dt>5. </dt><dd><div id="spr-def.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="spr-def.TF.1.6"><p class="no_margin">A single report of <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> involving <i>SPR</i> is <a href="/clinvar/variation/60181/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">listed in ClinVar</a>. In addition to <i>SPR</i>, this deletion involves <i>EMX1</i> and <i>SXN5</i>. No clinical details are provided and thus no conclusions can be drawn regarding the impact of deletion of <i>SPR</i>.</p></div></dd></dl></div></div></div><p><b>Characteristic CSF abnormalities of neurotransmitters and pterins</b> include:</p><ul><li class="half_rhythm"><div class="half_rhythm">Decreased levels of homovanillic acid (HVA) and 5-hyroxyindolacetic acid (5-HIAA);</div></li><li class="half_rhythm"><div class="half_rhythm">Normal to slightly increased levels of neopterin;</div></li><li class="half_rhythm"><div class="half_rhythm">Increased levels of total biopterin, dihydrobiopterin (BH2), and sepiapterin [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>].</div><div class="half_rhythm">Note: (1) CSF should be collected using standardized protocols and analyzed by a laboratory with appropriate age-related reference ranges [<a class="bk_pop" href="#spr-def.REF.hyland.1993.10">Hyland et al 1993</a>, <a class="bk_pop" href="#spr-def.REF.br_utigam.2002.287">Br&#x000e4;utigam et al 2002</a>]. (2) Normal values vary by lab and by age.</div></li></ul></div></div><div id="spr-def.Clinical_Characteristics"><h2 id="_spr-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="spr-def.Clinical_Description"><h3>Clinical Description</h3><p>The phenotypic spectrum of sepiapterin reductase deficiency (SRD) has not been completely elucidated due to the small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date, lack of systematic diagnostic evaluation and long-term follow up, and the absence of data on the prevalence and natural history of findings in untreated individuals. Of particular note, severity varies: some individuals manifest significant motor and cognitive deficits and others only minimal findings. Those with minimal findings may present at an older age or be identified because of the diagnosis of SRD in a sib [<a class="bk_pop" href="#spr-def.REF.arrabal.2011.183">Arrabal et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>].</p><p>Clinical features in 38 individuals with SRD are summarized by <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al [2012]</a>. A few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals not included in this review and described elsewhere have additional features [<a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>, <a class="bk_pop" href="#spr-def.REF.clot.2009.1753">Clot et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>, <a class="bk_pop" href="#spr-def.REF.koht.2014.7">Koht et al 2014</a>].</p><p><b>Clinical features present in more than 65% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</b> include motor and speech delay, axial hypotonia, dystonia, weakness, oculogyric crises, and diurnal fluctuation of symptoms with sleep benefit. Other common features include parkinsonian signs (tremor, bradykinesia, masked facies, rigidity), limb hypertonia, hyperreflexia, intellectual disability, psychiatric and/or behavioral abnormalities, autonomic dysfunction, and sleep disturbances (hypersomnolence, drowsiness, difficulty initiating or maintaining sleep related to alteration of the sleep-wake circadian rhythm).</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have nonspecific features in infancy including developmental delays and axial hypotonia. In the next few years other features that may develop include limb hypertonia, hyperreflexia, dystonia, and more apparent diurnal fluctuation and sleep disturbance.</p><p>In some instances, dystonia may present as paroxysmal stiffening of limbs and/or trunk with gaze deviation and tremor of the tongue, limbs, and/ or head [<a class="bk_pop" href="#spr-def.REF.dill.2012.e29">Dill et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>].</p><p><b>Numerous rarely reported findings</b> overlap with those typical of other disorders of monoamine neurotransmitter biosynthesis (see <a href="#spr-def.Differential_Diagnosis">Differential Diagnosis</a>).</p><p>Seizures (mostly febrile) occasionally occur, though frequency may be over-reported as oculogyric crises and paroxysmal stiffening episodes may be confused with seizures.</p><p>A few reports note low birth weight [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>], poor somatic growth [<a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>], and/or microcephaly [<a class="bk_pop" href="#spr-def.REF.blau.1998.433">Blau et al 1998</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>].</p><p>During later childhood, abnormalities in behavior and cognition become more apparent. These may be under-reported due to the prominence of the motor features.</p><p>While many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have intellectual disability, others with mild learning disabilities or normal cognition have been reported.</p><p>Psychiatric and/or behavioral findings most commonly include inattention, irritability, and anxiety; however, a wide range of symptoms may occur. It is hypothesized (though not yet proven) that early treatment may mitigate cognitive or psychiatric/behavioral abnormalities.</p></div><div id="spr-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Although several possible <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been suggested in individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SPR</i> pathogenic variants, due to the small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals these conclusions remain uncertain [<a class="bk_pop" href="#spr-def.REF.arrabal.2011.183">Arrabal et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]. Phenotypic variability is broad even among family members with identical pathogenic variants.</p><p>One individual <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the 5&#x02019; untranslated region with a mild form of L-dopa-responsive dystonia and reduced SR activity in fibroblasts has been reported [<a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>].</p></div><div id="spr-def.Nomenclature"><h3>Nomenclature</h3><p>Two individuals originally reported as having "central" dihydropteridine reductase (DHPR) deficiency [<a class="bk_pop" href="#spr-def.REF.blau.1998.433">Blau et al 1998</a>, <a class="bk_pop" href="#spr-def.REF.blau.1999.216">Blau et al 1999</a>] were later diagnosed with SRD [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>].</p></div><div id="spr-def.Prevalence"><h3>Prevalence</h3><p>No data are available on the prevalence of SRD.</p><p>A total of approximately 50 probands have been reported to date [<a class="bk_pop" href="#spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; et al 2001a</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>, <a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>, <a class="bk_pop" href="#spr-def.REF.neville.2005.2291">Neville et al 2005</a>, <a class="bk_pop" href="#spr-def.REF.abeling.2006.116">Abeling et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.echenne.2006.308">Echenne et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2006.2032">Friedman et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.verbeek.2008.403">Verbeek et al 2008</a>, <a class="bk_pop" href="#spr-def.REF.clot.2009.1753">Clot et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.kusmierska.2009.s5">Kusmierska et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.leusemenescu.2010.307">Leu-Semenescu et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.mazzuca.2010">Mazzuca et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.wali.2010.954">Wali et al 2010</a>, <a class="bk_pop" href="#spr-def.REF.arrabal.2011.183">Arrabal et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.dill.2012.e29">Dill et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.thibert.2012.79">Thibert et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.leuzzi.2013.2141">Leuzzi et al 2013</a>, <a class="bk_pop" href="#spr-def.REF.koht.2014.7">Koht et al 2014</a>].</p><p>SRD may be under-recognized due to lack of awareness.</p></div></div><div id="spr-def.Genetically_Related_Allelic_Diso"><h2 id="_spr-def_Genetically_Related_Allelic_Diso_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>SPR</i>.</p></div><div id="spr-def.Differential_Diagnosis"><h2 id="_spr-def_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>L-dopa-responsive motor disorders</b></p><ul><li class="half_rhythm"><div><b>Monoamine neurotransmitter disorders.</b> Defects in the synthesis of the monoamine neurotransmitters dopamine, serotonin, epinephrine, and norepinephrine result in a heterogeneous group of disorders. Neurologic manifestations of several of these disorders may respond to treatment with L-dopa [<a class="bk_pop" href="#spr-def.REF.nygaard.1991.174">Nygaard et al 1991</a>, <a class="bk_pop" href="#spr-def.REF.furukawa.1999.709">Furukawa &#x00026; Kish 1999</a>] including SRD and the following:</div><ul><li class="half_rhythm"><div><a href="/books/n/gene/drd/"><b>DYT-GCH1/GTP cyclohydrolase 1-deficient dopa-responsive dystonia</b></a> is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral levodopa. The average age of onset is approximately six years. This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms. Initial symptoms are often gait difficulties attributable to flexion-inversion (equinovarus posture) of the foot. Occasionally, initial symptoms are arm dystonia, postural tremor of the hand, or slowness of movements. Brisk deep-tendon reflexes in the legs, ankle clonus, and/or the striatal toe (dystonic extension of the big toe) are present in many <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. In general, gradual progression to generalized dystonia is observed. Intellectual, cerebellar, sensory, and autonomic disturbances do not occur. Manifestations of sepiapterin reductase deficiency typically begin earlier than those in DYT-GCH1/GTP cyclohydrolase 1-deficient dopa-responsive dystonia, although individuals with mild findings of SRD may mimic this condition.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/thdrd/"><b>DYT-TH/tyrosine hydroxylase deficiency</b></a> is associated with a broad phenotypic spectrum that mirrors that observed in SRD. Based on severity of symptoms/signs as well as responsiveness to levodopa therapy, clinical phenotypes caused by <i>TH</i> pathogenic variants are divided into (1) TH-deficient dopa-responsive dystonia (DRD: the mild form of TH deficiency [DYT5b]), (2) TH-deficient infantile parkinsonism with motor delay (the severe form), and (3) TH-deficient progressive infantile encephalopathy (the very severe form). In contrast to SRD, individuals with DYT-TH do not have abnormalities of pterin or serotonin metabolism, though clinically these distinctions are not always apparent.</div></li><li class="half_rhythm"><div><b>Aromatic L-amino acid decarboxylase (AADC) deficiency</b> is a disorder of biogenic amine metabolism that leads to combined deficiency of serotonin and all catecholamines. Similar to SRD, symptoms begin in infancy and are characterized by developmental delay, axial hypotonia with limb hypertonia, dystonia and parkinsonian features including bradykinesia and rigidity. Chorea and oculogyric crises may be present. Autonomic and endocrinologic abnormalities also occur. Diurnal fluctuation may be present though is generally less pronounced than in SRD. A rare subset of patients show therapeutic benefit with L-dopa [<a class="bk_pop" href="#spr-def.REF.chang.2004.435">Chang et al, 2004</a>] or with other dopaminergic agents (dopamine agonists, methylphenydate, MAO inhibitors) that do not require AADC to be active.</div></li></ul></li><li class="half_rhythm"><div><b>Other.</b> Improvement with L-dopa may also occur in juvenile Parkinson disease (see below) or may be a nonspecific feature of several motor disorders.</div></li></ul><p><b>Dystonia</b> may be a prominent, though often late and not universal feature of SRD [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]. For a detailed differential for dystonia, see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>.</p><p><b>Cerebral palsy.</b> Sepiapterin reductase deficiency (SRD) often presents with nonspecific symptoms including global delay with hypotonia or a nonspecific gait disorder, often with cognitive impairment. Hyperreflexia and/or striatal toe (simulating a Babinski reflex but without fanning of the toes) may be present. Oculogyric crises, if recognized, are a frequent clue to dopamine deficiency syndrome; however, as other neurologic manifestations are nonspecific, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be misdiagnosed with cerebral palsy or an undefined L-dopa-responsive motor disorder [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]. These features as well as the varied and nonspecific presentation may lead to a misdiagnosis of cerebral palsy [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]. The differential for global delay and cerebral palsy are broad and beyond the scope of this review.</p><p>A suggested algorithm for evaluation of patients with global delay with hypotonia, dystonia, or L-dopa-responsive motor disorder may be found in <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al [2012]</a>.</p><p><b>Juvenile Parkinson disease.</b> Parkinsonian signs are frequent and may suggest juvenile Parkinson disease, most commonly caused by mutation of <i>PRKN</i>, <i>PINK1</i>, <i>DJ1</i>, or <i>ATP13A2</i>. Typically manifestations in SRD begin at an earlier age than juvenile Parkinson disease. Differentiation between SRD and juvenile Parkinson disease is critical for prognostication and therapeutic management: Individuals with SRD may derive sustained benefit from L-dopa whereas those with juvenile Parkinson disease will develop complications with L-dopa therapy (and although it is controversial, dopamine agonists should be considered instead).</p><p><b>Disorders of biopterin metabolism.</b> Tetrahydrobiopterin (BH<sub>4</sub>) deficiencies are caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in one of the genes involving biosynthesis or recycling of BH<sub>4</sub>, a cofactor in the phenylalanine, tyrosine, and tryptophan hydroxylation reaction. These genes and disorders are summarized in <a class="figpopup" href="/books/NBK304122/table/spr-def.T.tetrahydrobiopterin_bh4_defici/?report=objectonly" target="object" rid-figpopup="figsprdefTtetrahydrobiopterinbh4defici" rid-ob="figobsprdefTtetrahydrobiopterinbh4defici">Table 2</a>.</p><div id="spr-def.T.tetrahydrobiopterin_bh4_defici" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Tetrahydrobiopterin (BH<sub>4</sub>) Deficiencies</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK304122/table/spr-def.T.tetrahydrobiopterin_bh4_defici/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spr-def.T.tetrahydrobiopterin_bh4_defici_lrgtbl__"><table><thead><tr><th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Gene</th><th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Disorder</th><th id="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OMIM</th></tr></thead><tbody><tr><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>GCH1</i></td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GTP cyclohydrolase I deficiency</td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://omim.org/entry/233910" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">233910</a></td></tr><tr><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>PTS</i></td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency</td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://omim.org/entry/261640" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">261640</a></td></tr><tr><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>PCBD1</i></td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pterin-4a-alpha-carbinolamine dehydratase deficiency</td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://omim.org/entry/264070" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">264070</a></td></tr><tr><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><i>QDPR</i></td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dihydropteridine reductase (DHPR) deficiency</td><td headers="hd_h_spr-def.T.tetrahydrobiopterin_bh4_defici_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="http://omim.org/entry/261630" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">261630</a></td></tr></tbody></table></div></div><p><b>Other.</b> Symptoms, which result from impaired phenylalanine homeostasis and serotonin and catecholamine biosynthesis, overlap significantly with SRD. Unlike SRD, these conditions typically (though not always) present with hyperphenylalaninemia detected on <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a>. More information on the BH<sub>4</sub> deficiencies can be found at <a href="http://www.biopku.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.biopku.org</a>.</p></div><div id="spr-def.Management"><h2 id="_spr-def_Management_">Management</h2><div id="spr-def.Evaluations_Following_Initial_Di"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with sepiapterin reductase deficiency (SRD), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Consultation with a neurologist</div></li><li class="half_rhythm"><div>Physical therapy, occupational therapy, and speech therapy evaluations depending on severity of manifestations</div></li><li class="half_rhythm"><div>Neuropsychological evaluation depending on the severity of manifestations</div></li><li class="half_rhythm"><div>Social services consultation depending on the severity of manifestations</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="spr-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Therapy is aimed at correcting central nervous system (CNS) neurotransmitter deficits.</p><p>Recommended treatments are based on the few reported cases in the literature and extrapolation from strategies employed in treatment of other neurotransmitter disorders.</p><p>While the medications discussed below reduce manifestations of SRD, response can range from complete resolution to partial improvement. These medications most consistently correct motor abnormalities while in some cognitive manifestations remain more refractory.</p><p>Often, medications must be prescribed "off-label" without established pediatric dose ranges [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>L-dopa</b> (0.1-16 mg/kg/day) in combination with 10%-25% carbidopa (or another peripheral decarboxylase inhibitor) is the main therapy to correct CNS dopamine deficiency. Optimal therapeutic level is determined by clinical response.</div><div class="half_rhythm">Note: (1) Dose-related dyskinesias may occur [<a class="bk_pop" href="#spr-def.REF.abeling.2006.116">Abeling et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.neville.2007.85">Neville 2007</a>, <a class="bk_pop" href="#spr-def.REF.arrabal.2011.183">Arrabal et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]; they can be eliminated in most instances with reduced dosage or addition of a dopamine agonist to reduce fluctuations in dopaminergic stimulation [<a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>]. (2) Gastrointestinal side effects such as nausea may be reduced by increasing the proportion of administered carbidopa. (3) Although not reported, it is theoretically possible that individuals with SRD receiving high-dose L-dopa could develop cerebral folate deficiency and require supplementation with folinic acid (as has been observed in L-aromatic amino acid decarboxylase deficiency [<a class="bk_pop" href="#spr-def.REF.brun.2010.64">Brun et al 2010</a>]).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>5-hydroxytryptophan</b> (5-HTP) (1-6 mg/kg/day) also in combination with <b>carbidopa</b> to correct CNS serotonin deficiency has shown additional clinical benefit in some.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Tetrahydrobiopterin</b> (BH<sub>4</sub>; sapropterin dihydrocloride) may in theory be of benefit, although none was reported in four patients treated for only a short time [<a class="bk_pop" href="#spr-def.REF.friedman.2006.2032">Friedman et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>]. Note that it is difficult to achieve adequate CNS levels of BH<sub>4</sub> due to limited transport across the blood brain barrier.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Other agents</b> used when L-dopa/5HTP/carbidopa are not tolerated or sufficiently effective which have shown benefit in single or small numbers of patients include:</div><ul><li class="half_rhythm"><div>Monoamine oxidase inhibitors (selegeline)</div></li><li class="half_rhythm"><div>Serotonin reuptake inhibitors (sertraline)</div></li><li class="half_rhythm"><div>Melatonin</div></li><li class="half_rhythm"><div>Dopamine agonists (bromocriptine, pramipexole)</div></li><li class="half_rhythm"><div>Anticholinergics</div></li><li class="half_rhythm"><div>Methylphenidate</div></li></ul></li></ul></div><div id="spr-def.Prevention_of_Secondary_Complica"><h3>Prevention of Secondary Complications</h3><p>Physical, occupational, and speech therapy may improve or maintain function.</p></div><div id="spr-def.Surveillance"><h3>Surveillance</h3><p>Data are insufficient to determine how frequently CSF levels of dopamine and serotonin metabolites should be evaluated and whether these levels should be used to adjust medication doses. Practices range from at least annual assessment of CNS neurotransmitter metabolites to adjustment of neurotransmitter precursor therapy based solely on clinical manifestations.</p><p>Because clinical manifestations are more difficult to assess in children, it would seem prudent to evaluate CSF neurotransmitter metabolites two to four times yearly in children younger than age two years and at least yearly in children younger than age ten years.</p><p>Note: Plasma prolactin levels may inversely correlate with CNS dopamine levels but are neither a sensitive nor specific marker [<a class="bk_pop" href="#spr-def.REF.leuzzi.2002.1241">Leuzzi et al 2002</a>, <a class="bk_pop" href="#spr-def.REF.furukawa.2003.269">Furukawa et al 2003</a>, <a class="bk_pop" href="#spr-def.REF.concolino.2008.s193">Concolino et al 2008</a>].</p></div><div id="spr-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Although adverse events with specific agents have not been reported in persons with SRD, several should be avoided on a theoretic basis including:</p><ul><li class="half_rhythm"><div>Sulfa drugs, which impair BH<sub>4</sub> biosynthesis by inhibiting sepiapterin reductase [<a class="bk_pop" href="#spr-def.REF.haruki.2013.987">Haruki et al 2013</a>]</div></li><li class="half_rhythm"><div>Methotrexate, which inhibits dihydropteridine reductase, an enzyme involved in BH<sub>4</sub> regeneration [<a class="bk_pop" href="#spr-def.REF.woody.1990.639">Woody &#x00026; Brewster 1990</a>]</div></li><li class="half_rhythm"><div>Nitrous oxide, which may impair folate metabolism [<a class="bk_pop" href="#spr-def.REF.wyatt.1999.307">Wyatt &#x00026; Gill 1999</a>]</div></li><li class="half_rhythm"><div>Neuroleptics and other dopamine antagonists (e.g., metoclopramide)</div></li></ul></div><div id="spr-def.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>While no data on outcomes are available, it is appropriate to use <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>SPR</i> pathogenic variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and/or analysis of CSF neurotransmitter metabolites and pterins to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as soon as possible those who would benefit from early initiation of treatment to correct CNS dopamine and serotonin deficiency.</p><p>See <a href="#spr-def.Related_Genetic_Counseling_Issue">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="spr-def.Pregnancy_Management"><h3>Pregnancy Management</h3><p>No pregnancies have been reported to date in women with SRD.</p><p>Based on reports that suggest that L-dopa may be advantageous during pregnancy in women with GTP cyclohydrolase 1-deficient dopa-responsive dystonia (<a href="/books/n/gene/drd/">DYT-GCH1</a>), it would seem prudent for women with SRD to continue L-dopa therapy during pregnancy [<a class="bk_pop" href="#spr-def.REF.trendergerhard.2009.839">Trender-Gerhard et al 2009</a>, <a class="bk_pop" href="#spr-def.REF.watanabe.2012.559">Watanabe &#x00026; Matsubara 2012</a>].</p></div><div id="spr-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="spr-def.Genetic_Counseling"><h2 id="_spr-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="spr-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Sepiapterin reductase deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="spr-def.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are generally asymptomatic and are not at risk of developing the disorder. Current data are insufficient to associate clinical manifestations with heterozygosity for an <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, several anecdotal reports have raised this possibility, including the following:</div><ul><li class="half_rhythm"><div>An individual with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the 5&#x02019; untranslated region and a mild L-dopa-responsive dystonia <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>]</div></li><li class="half_rhythm"><div>Fibromyalgia which segregated with <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status in one small <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> [<a class="bk_pop" href="#spr-def.REF.bainbridge.2011.87re3">Bainbridge et al 2011</a>]</div></li><li class="half_rhythm"><div>The presence of other manifestations including dystonia and parkinsonism in relatives (who had not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>) of individuals with SRD [<a class="bk_pop" href="#spr-def.REF.friedman.2006.2032">Friedman et al 2006</a>, <a class="bk_pop" href="#spr-def.REF.lohmann.2012.191">Lohmann et al 2012</a>]</div></li></ul></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are usually not at risk of developing the disorder (see <b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b>).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Individuals with sepiapterin reductase deficiency have not been reported to reproduce; however, only a few identified individuals are of childbearing age.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="spr-def.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SPR</i> pathogenic variants in the family.</p></div><div id="spr-def.Related_Genetic_Counseling_Issue"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#spr-def.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who have or are at risk of having one or more <i>SPR</i> pathogenic variants.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="spr-def.Prenatal_Testing_and_Preimplanta"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SPR</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible. Because individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SPR</i> pathogenic variants may be asymptomatic, predicting the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> based on results of prenatal testing may not be reliable.</p></div></div><div id="spr-def.Resources"><h2 id="_spr-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Dystonia Society</b></div><div>89 Albert Embankment</div><div>3rd Floor</div><div>London SE1 7TP</div><div>United Kingdom</div><div><b>Phone:</b> 0845 458 6211; 0845 458 6322 (Helpline)</div><div><b>Fax:</b> 0845 458 6311</div><div><b>Email:</b> support@dystonia.org.uk</div><div><a href="http://www.dystonia.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.dystonia.org.uk</a></div></li><li class="half_rhythm"><div><b>Dystonia Medical Research Foundation</b></div><div>One East Wacker Drive</div><div>Suite 1730</div><div>Chicago IL 60601-1905</div><div><b>Phone:</b> 800-377-3978 (toll-free); 312-755-0198</div><div><b>Fax:</b> 312-803-0138</div><div><b>Email:</b> dystonia@dystonia-foundation.org</div><div><a href="http://www.dystonia-foundation.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.dystonia-foundation.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>Global Dystonia Registry</b></div><div><a href="http://www.globaldystoniaregistry.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.globaldystoniaregistry.org</a></div></li><li class="half_rhythm"><div><b>International Working Group on Neurotransmitter Related Disorders (iNTD) Patient Registry</b></div><div><a href="https://intd-registry.org/index.php?id=about" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">About iNTD</a></div></li></ul></div><div id="spr-def.Molecular_Genetics"><h2 id="_spr-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="spr-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Sepiapterin Reductase Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK304122/table/spr-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spr-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_spr-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_spr-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_spr-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_spr-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_spr-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_spr-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_spr-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6697" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SPR</i></a></td><td headers="hd_b_spr-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6697" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_spr-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P35270" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sepiapterin reductase</a></td><td headers="hd_b_spr-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.biopku.org/home/biomdb.asp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">BIOMDBdb : Database of Mutations Causing BH4 Deficiencies and other PND (SPR)</a><br /><a href="http://databases.lovd.nl/shared/genes/SPR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SPR database</a></td><td headers="hd_b_spr-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SPR" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SPR</a></td><td headers="hd_b_spr-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SPR[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SPR</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="spr-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="spr-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Sepiapterin Reductase Deficiency (<a href="/omim/182125,612716" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK304122/table/spr-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spr-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/182125" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">182125</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SEPIAPTERIN REDUCTASE; SPR</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612716" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612716</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DYSTONIA, DOPA-RESPONSIVE, DUE TO SEPIAPTERIN REDUCTASE DEFICIENCY</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>SPR</i> spans 4.8 kb and comprises three exons. There is no evidence for alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants [<a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK304122/#spr-def.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Seventeen pathogenic variants have been reported in <i>SPR</i> [<a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.koht.2014.7">Koht et al 2014</a>]. Pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> except for a single individual heterozygous for a <i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the 5' untranslated region with a mild form of L-dopa-responsive dystonia and reduced sepiapterin reductase activity in fibroblasts [<a class="bk_pop" href="#spr-def.REF.steinberger.2004.187">Steinberger et al 2004</a>]. The authors did not report whether <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> was performed to evaluate for deletion on the other <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</p><p>Known pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and frameshift. Pathogenic variants have been found in all three exons, the 5&#x02019; untranslated region, and the <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> region in the <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> acceptor consensus sequence preceding <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 [<a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>, <a class="bk_pop" href="#spr-def.REF.koht.2014.7">Koht et al 2014</a>].</p><p>Homozygosity for the <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variant c.596-2A&#x0003e;G was the most common <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> found in a cohort of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from Malta, suggesting a possible <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> [<a class="bk_pop" href="#spr-def.REF.neville.2005.2291">Neville et al 2005</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>, <a class="bk_pop" href="#spr-def.REF.friedman.2012.520">Friedman et al 2012</a>].</p><div id="spr-def.T.spr_pathogenic_variants_discus" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>SPR</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK304122/table/spr-def.T.spr_pathogenic_variants_discus/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__spr-def.T.spr_pathogenic_variants_discus_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.596-2A&#x0003e;G</td><td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></td><td headers="hd_h_spr-def.T.spr_pathogenic_variants_discus_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_003124.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003124<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_003115.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003115<wbr style="display:inline-block"></wbr>​.1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the author. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>SPR</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> encodes a monomer of 261 amino acids. Sepiapterin reductase is a homodimer with a predicted molecular mass of 56 kd [<a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Biallelic pathogenic variants in <i>SPR</i> result in dysfunctional SR protein, decreased synthesis of BH<sub>4,</sub> and accumulation of BH<sub>2</sub> and sepiapterin in the central nervous system. Alternative pathways in the liver and other tissues compensate for lack of sepiapterin reductase and account for normal phenylalanine levels and lack of neurotransmitter or pterin abnormalities in the periphery [<a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>].</p><p>Symptoms arise primarily from impaired central nervous system serotonin and catecholamine production. Reduced neurotransmitter production is the result of both reduced activity of tyrosine and tryptophan hydroxylases due to reduced levels of BH<sub>4</sub> cofactor as well as direct inhibition of these hydroxylases by accumulated BH<sub>2</sub> [<a class="bk_pop" href="#spr-def.REF.bonaf_.2006">Bonaf&#x000e9; 2006</a>]. In addition, altered BH<sub>4</sub>:BH<sub>2</sub> ratios may uncouple nitric oxide synthase (an enzyme dependent on the BH<sub>4</sub> cofactor), and increase free radical production [<a class="bk_pop" href="#spr-def.REF.blau.2001.172">Blau et al 2001</a>, <a class="bk_pop" href="#spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; et al 2001b</a>]. The effect of these perturbations on the clinical picture is unclear.</p><p>Neurotransmitter deficiency is primarily responsible for clinical manifestations; however, several lines of evidence suggest that sepiapterin reductase deficiency may also affect maturation of the dopaminergic system as well as stabilization of the protein tyrosine hydroxylase [<a class="bk_pop" href="#spr-def.REF.okuno.1985.2633">Okuno &#x00026; Fujisawa1985</a>, <a class="bk_pop" href="#spr-def.REF.takazawa.2008.787">Takazawa et al 2008</a>, <a class="bk_pop" href="#spr-def.REF.homma.2011.1445">Homma et al 2011</a>, <a class="bk_pop" href="#spr-def.REF.homma.2013.70">Homma et al 2013</a>].</p></div><div id="spr-def.References"><h2 id="_spr-def_References_">References</h2><div id="spr-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.abeling.2006.116">Abeling NG, Duran M, Bakker HD, Stroomer L, Thony B, Blau N, Booij J, Poll-The BT. Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">89</span>:116–20.</span> [<a href="/pubmed/16650784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16650784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.arrabal.2011.183">Arrabal L, Teresa L, Sanchez-Alcudia R, Castro M, Medrano C, Gutierrez-Solana L, Roldan S, Ormazabal A, Perez-Cerda C, Merinero B, Perez B, Artuch R, Ugarte M, Desviat LR. Genotype-phenotype correlations in sepiapterin reductase deficiency. A splicing defect accounts for a new phenotypic variant. <span><span class="ref-journal">Neurogenetics. </span>2011;<span class="ref-vol">12</span>:183–91.</span> [<a href="/pubmed/21431957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21431957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.bainbridge.2011.87re3">Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, Reid JG, Fink JK, Morgan MB, Gingras MC, Muzny DM, Hoang LD, Yousaf S, Lupski JR, Gibbs RA. Whole-genome sequencing for optimized patient management. <span><span class="ref-journal">Sci Transl Med. </span>2011;<span class="ref-vol">3</span>:87re3.</span> [<a href="/pmc/articles/PMC3314311/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3314311</span></a>] [<a href="/pubmed/21677200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21677200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.blau.2001.172">Blau N, Bonafe L, Thony B. Tetrahydrobiopterin deficiencies without hyperphenylalaniemia: diagnosis and genetics of Dopa-responsive dystonia and sepiapterin reductase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2001;<span class="ref-vol">74</span>:172–85.</span> [<a href="/pubmed/11592814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11592814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.blau.1998.433">Blau N, Thony B, Renneberg A, Arnold LA, Hyland K. Dihydropteridine reductase deficiency localized to the central nervous system. <span><span class="ref-journal">J Inherit Metab Dis. </span>1998;<span class="ref-vol">21</span>:433–4.</span> [<a href="/pubmed/9700606" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9700606</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.blau.1999.216">Blau N, Thony B, Renneberg A, Penzien JM, Hyland K, Hoffmann GF. Variant of dihydropteridine reductase deficiency without hyperphenylalaninaemia: effect of oral phenylalanine loading. <span><span class="ref-journal">J Inherit Metab Dis. </span>1999;<span class="ref-vol">22</span>:216–20.</span> [<a href="/pubmed/10384371" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10384371</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.bonaf_.2006">Bonaf&#x000e9; L. Sepiapterin reductase deficiency. In: Blau N, ed. <em>PKU and BH4 Advances in Phenylketonuria and Tetrahydrobiopterin.</em> Heilbronn: SPS Verlagsgesellschaft. 2006:593-611.</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.bonaf_.2001a.477">Bonaf&#x000e9; L, Thony B, Leimbacher W, Kierat L, Blau N. Diagnosis of dopa-responsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. <span><span class="ref-journal">Clin Chem. </span>2001a;<span class="ref-vol">47</span>:477–85.</span> [<a href="/pubmed/11238300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11238300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.bonaf_.2001b.269">Bonaf&#x000e9; L, Thony B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. <span><span class="ref-journal">Am J Hum Genet. </span>2001b;<span class="ref-vol">69</span>:269–77.</span> [<a href="/pmc/articles/PMC1235302/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235302</span></a>] [<a href="/pubmed/11443547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11443547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.br_utigam.2002.287">Br&#x000e4;utigam C, Weykamp C, Hoffmann GF, Wevers RA. Neurotransmitter metabolites in CSF: an external quality control scheme. <span><span class="ref-journal">J Inherit Metab Dis. </span>2002;<span class="ref-vol">25</span>:287–98.</span> [<a href="/pubmed/12227459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12227459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.brun.2010.64">Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, Lee WT, Willemsen MA, Verbeek MM, Wassenberg T, R&#x000e9;gal L, Orcesi S, Tonduti D, Accorsi P, Testard H, Abdenur JE, Tay S, Allen GF, Heales S, Kern I, Kato M, Burlina A, Manegold C, Hoffmann GF, Blau N. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. <span><span class="ref-journal">Neurology. </span>2010;<span class="ref-vol">75</span>:64–71.</span> [<a href="/pubmed/20505134" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20505134</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.chang.2004.435">Chang YT, Sharma R, Marsh JL, McPherson JD, Bedell JA, Knust A, Brautigam C, Hoffmann GF, Hyland K. Levodopa-responsive aromatic L-amino acid decarboxylase deficiency. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:435–8.</span> [<a href="/pubmed/14991824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14991824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.clot.2009.1753">Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabro B, Landrieu P, Nguyen K, Ponsot G, Abada M, Doummar D, Damier P, Gil R, Thobois S, Ward AJ, Hutchinson M, Toutain A, Picard F, Camuzat A, Fedirko E, San C, Bouteiller D, LeGuern E, Durr A, Vidailhet M, Brice A. the French Dystonia Network. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>:1753–63.</span> [<a href="/pubmed/19491146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19491146</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.concolino.2008.s193">Concolino D, Muzzi G, Rapsomaniki M, Moricca MT, Pascale MG, Strisciuglio P. Serum prolactin as a tool for the follow-up of treated DHPR-deficient patients. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span>:S193–7.</span> [<a href="/pubmed/18425437" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18425437</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.dill.2012.e29">Dill P, Wagner M, Somerville A, Thony B, Blau N, Weber P. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. <span><span class="ref-journal">Neurology. </span>2012;<span class="ref-vol">78</span>:e29–32.</span> [<a href="/pubmed/22291068" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22291068</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.echenne.2006.308">Echenne B, Roubertie A, Assmann B, Lutz T, Penzien JM, Thony B, Blau N, Hoffmann GF. Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. <span><span class="ref-journal">Pediatr Neurol. </span>2006;<span class="ref-vol">35</span>:308–13.</span> [<a href="/pubmed/17074599" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17074599</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.friedman.2006.2032">Friedman J, Hyland K, Blau N, MacCollin M. Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:2032–5.</span> [<a href="/pubmed/17159114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17159114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.friedman.2012.520">Friedman J, Roze E, Abdenur JE, Chang R, Gasperini S, Saletti V, Wali GM, Eiroa H, Neville B, Felice A, Parascandalo R, Zafeiriou DI, Arrabal-Fernandez L, Dill P, Eichler FS, Echenne B, Gutierrez-Solana LG, Hoffmann GF, Hyland K, Kusmierska K, Tijssen MAJ, Lutz T, Mazzuca M, Penzien J, Poll-The BT, Sykut-Cegielska J, Szymanska K, Thony B, Blau N. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. <span><span class="ref-journal">Ann Neurol. </span>2012;<span class="ref-vol">71</span>:520–30.</span> [<a href="/pubmed/22522443" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22522443</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.furukawa.2003.269">Furukawa Y, Guttman M, Wong H, Farrell SA, Furtado S, Kish SJ. Serum prolactin in symptomatic and asymptomatic dopa-responsive dystonia due to a GCH1 mutation. <span><span class="ref-journal">Neurology. </span>2003;<span class="ref-vol">61</span>:269–70.</span> [<a href="/pubmed/12874420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12874420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.furukawa.1999.709">Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. <span><span class="ref-journal">Mov Disord. </span>1999;<span class="ref-vol">14</span>:709–15.</span> [<a href="/pubmed/10495030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10495030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.haruki.2013.987">Haruki H, Pedersen MG, Gorska KI, Pojer F, Johnsson K. Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs. <span><span class="ref-journal">Science. </span>2013;<span class="ref-vol">340</span>:987–91.</span> [<a href="/pubmed/23704574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23704574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.homma.2013.70">Homma D, Katoh S, Tokuoka H, Ichinose H. The role of tetrahydrobiopterin and catecholamines in the developmental regulation of tyrosine hydroxylase level in the brain. <span><span class="ref-journal">J Neurochem. </span>2013;<span class="ref-vol">126</span>:70–81.</span> [<a href="/pubmed/23647001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23647001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.homma.2011.1445">Homma D, Sumi-Ichinose C, Tokuoka H, Ikemoto K, Nomura T, Kondo K, Katoh S, Ichinose H. Partial biopterin deficiency disturbs postnatal development of the dopaminergic system in the brain. <span><span class="ref-journal">J Biol Chem. </span>2011;<span class="ref-vol">286</span>:1445–52.</span> [<a href="/pmc/articles/PMC3020753/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3020753</span></a>] [<a href="/pubmed/21062748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21062748</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.hyland.1997.1290">Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS, Jacobson RD, Rost-Ruffner E, Trugman JM. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. <span><span class="ref-journal">Neurology. </span>1997;<span class="ref-vol">48</span>:1290–7.</span> [<a href="/pubmed/9153460" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9153460</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.hyland.1993.10">Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. <span><span class="ref-journal">Pediatr Res. </span>1993;<span class="ref-vol">34</span>:10–4.</span> [<a href="/pubmed/7689195" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7689195</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.koht.2014.7">Koht J, Rengmark A, Opladen T, Bj&#x000f8;rnar&#x000e5; KA, Selberg T, Tallaksen CM, Blau N, Toft M. Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene. <span><span class="ref-journal">Acta Neurol Scand Suppl. </span>2014;(198):7–12.</span> [<a href="/pubmed/24588500" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24588500</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.kusmierska.2009.s5">Kusmierska K, Jansen EE, Jakobs C, Szymanska K, Malunowicz E, Meilei D, Thony B, Blau N, Tryfon J, Rokicki D, Pronicka E, Sykut-Cegielska J. Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up. <span><span class="ref-journal">J Inherit Metab Dis. </span>2009;<span class="ref-vol">32</span> Suppl 1:S5–10.</span> [<a href="/pubmed/19130291" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19130291</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.leusemenescu.2010.307">Leu-Semenescu S, Arnulf I, Decaix C, Moussa F, Clot F, Boniol C, Touitou Y, Levy R, Vidailhet M, Roze E. Sleep and rhythm consequences of a genetically induced loss of serotonin. <span><span class="ref-journal">Sleep. </span>2010;<span class="ref-vol">33</span>:307–14.</span> [<a href="/pmc/articles/PMC2831424/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2831424</span></a>] [<a href="/pubmed/20337188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20337188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.leuzzi.2002.1241">Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1241–3.</span> [<a href="/pubmed/12391354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12391354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.leuzzi.2013.2141">Leuzzi V, Carducci C, Tolve M, Giannini MT, Angeloni A, Carducci C. Very early pattern of movement disorders in sepiapterin reductase deficiency. <span><span class="ref-journal">Neurology. </span>2013;<span class="ref-vol">81</span>:2141–2.</span> [<a href="/pubmed/24212389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24212389</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.lohmann.2012.191">Lohmann E, K&#x000f6;ro&#x0011f;lu &#x000c7;, Hanagasi HA, Dursun B, Tasan E, Tolun A. A homozygous frameshift mutation of sepiapterin reductase gene causing parkinsonism with onset in childhood. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2012;<span class="ref-vol">18</span>:191–3.</span> [<a href="/pubmed/22018912" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22018912</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.mazzuca.2010">Mazzuca M, Christa L, Damaj L, Plouin P, Dauvilliers Y, Rabier D, Clot F, Odent S, Benoist JF, De Lonlay P. Dopa-responsive hypersomnia in combined sepiapterin reductase (SR) and methyl malonyl CoA epimerase (MCEE) deficiency. Istanbul, Turkey: Annual Symposium of the Society for the Study of Inborn Errors of Metabolism; 2010.</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.neville.2007.85">Neville B. Congenital DOPA-responsive disorders: a diagnostic and therapeutic challenge to the cerebral palsies? <span><span class="ref-journal">Dev Med Child Neurol. </span>2007;<span class="ref-vol">49</span>:85.</span> [<a href="/pubmed/17253992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17253992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.neville.2005.2291">Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. <span><span class="ref-journal">Brain. </span>2005;<span class="ref-vol">128</span>:2291–6.</span> [<a href="/pubmed/16049044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16049044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.nygaard.1991.174">Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. <span><span class="ref-journal">Neurology. </span>1991;<span class="ref-vol">41</span>:174–81.</span> [<a href="/pubmed/1899474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1899474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.okuno.1985.2633">Okuno S, Fujisawa H. A new mechanism for regulation of tyrosine 3-monooxygenase by end product and cyclic AMP-dependent protein kinase. <span><span class="ref-journal">J Biol Chem. </span>1985;<span class="ref-vol">260</span>:2633–5.</span> [<a href="/pubmed/2857715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2857715</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.steinberger.2004.187">Steinberger D, Blau N, Goriuonov D, Bitsch J, Zuker M, Hummel S, Muller U. Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia. <span><span class="ref-journal">Neurogenetics. </span>2004;<span class="ref-vol">5</span>:187–90.</span> [<a href="/pubmed/15241655" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15241655</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.takazawa.2008.787">Takazawa C, Fujimoto K, Homma D, Sumi-Ichinose C, Nomura T, Ichinose H, Katoh S. A brain-specific decrease of the tyrosine hydroxylase protein in sepiapterin reductase-null mice--as a mouse model for Parkinson's disease. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2008;<span class="ref-vol">367</span>:787–92.</span> [<a href="/pubmed/18201550" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18201550</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.thibert.2012.79">Thibert R, Hyland K, Chiles J, Steinberg S, Eichler F. Levodopa response reveals sepiapterin reductase deficiency in a female heterozygote with adrenoleukodystrophy. <span><span class="ref-journal">JIMD Rep. </span>2012;<span class="ref-vol">3</span>:79–82.</span> [<a href="/pmc/articles/PMC3509860/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3509860</span></a>] [<a href="/pubmed/23430877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23430877</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.trendergerhard.2009.839">Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, Polke JM, Hanna MG, Davis MB, Wood NW, Bhatia KP. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2009;<span class="ref-vol">80</span>:839–45.</span> [<a href="/pubmed/19332422" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19332422</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.verbeek.2008.403">Verbeek MM, Willemsen MA, Wevers RA, Lagerwerf AJ, Abeling NGGM, Blau N, Thony B, Vargiami E, Zafeiriou DI. Two Greek siblings with sepiapterin reductase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>2008;<span class="ref-vol">94</span>:403–9.</span> [<a href="/pubmed/18502672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18502672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.wali.2010.954">Wali GM, Thony B, Blau N. Sepiapterin reductase deficiency: two Indian siblings with unusual clinical features. <span><span class="ref-journal">Mov Disord. </span>2010;<span class="ref-vol">25</span>:954–5.</span> [<a href="/pubmed/20222129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20222129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.watanabe.2012.559">Watanabe T, Matsubara S. Good obstetric outcome in a patient with Segawa disease. <span><span class="ref-journal">Arq Neuropsiquiatr. </span>2012;<span class="ref-vol">70</span>:559–60.</span> [<a href="/pubmed/22836471" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22836471</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.woody.1990.639">Woody RC, Brewster MA. Adverse effects of trimethoprim-sulfamethoxazole in a child with dihydropteridine reductase deficiency. <span><span class="ref-journal">Dev Med Child Neurol. </span>1990;<span class="ref-vol">32</span>:639–42.</span> [<a href="/pubmed/2391014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2391014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.wyatt.1999.307">Wyatt SS, Gill RS. An absolute contraindication to nitrous oxide. <span><span class="ref-journal">Anaesthesia. </span>1999;<span class="ref-vol">54</span>:307.</span> [<a href="/pubmed/10364889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10364889</span></a>]</div></li></ul></div><div id="spr-def.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="spr-def.REF.friedman.2014">Friedman J, Opladen T. L-dopa-responsive dystonia syndromes. In: Hoffmann G, Blau N, eds. <em>Congenital Neurotransmitter Disorders: A Clinical Approach.</em> New York, NY; Nova Biomedical. 2014:17-38.</div></li></ul></div></div><div id="spr-def.Chapter_Notes"><h2 id="_spr-def_Chapter_Notes_">Chapter Notes</h2><div id="spr-def.Acknowledgments"><h3>Acknowledgments</h3><p>Thank you to patients and families whose participation has enabled us to learn about sepiapterin reductase deficiency and bring benefit to individuals identified with this condition in the future.</p></div><div id="spr-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>1 July 2015 (me) Review posted live</div></li><li class="half_rhythm"><div>26 January 2015 (jf) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK304122</span><span class="label">PMID: <a href="/pubmed/26131547" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">26131547</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/schwann/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/scad/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK304122&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK304122/?report=reader">PubReader</a></li><li><a href="/books/NBK304122/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK304122" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK304122" style="display:none" title="Cite this Page"><div class="bk_tt">Friedman J. Sepiapterin Reductase Deficiency. 2015 Jul 1. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK304122/pdf/Bookshelf_NBK304122.pdf">PDF version of this page</a> (471K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#spr-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#spr-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#spr-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#spr-def.Genetically_Related_Allelic_Diso" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#spr-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#spr-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#spr-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#spr-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#spr-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#spr-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#spr-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6697[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SPR</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4083590" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4083590" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4083590" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4083590" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301610" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Tyrosine Hydroxylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y, Kish S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28541650" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> SLC39A14 Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tuschl K, Gregory A, Meyer E, Clayton PT, Hayflick SJ, Mills PB, Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28749637" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">SLC6A3</i>-Related Dopamine Transporter Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kurian MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301681" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furukawa Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=26131547" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=26131547" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04182f75f66d18aa7eef87">Sepiapterin Reductase Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Sepiapterin Reductase Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:17:19-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8B7252E03FE831000000000A29039C&amp;ncbi_session=CE8B7252E04182E1_2601SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK304122%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK304122&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK304122/&amp;ncbi_pagename=Sepiapterin Reductase Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B7252E04182E1_2601SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>